- Home
- MNY vs CVKD Comparison
MNY vs CVKD Comparison
Compare MNY & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNY
- CVKD
- Stock Information
- Founded
- MNY 2014
- CVKD 2022
- Country
- MNY Singapore
- CVKD United States
- Employees
- MNY N/A
- CVKD N/A
- Industry
- MNY
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- MNY
- CVKD Health Care
- Exchange
- MNY Nasdaq
- CVKD Nasdaq
- Market Cap
- MNY 43.9M
- CVKD 29.5M
- IPO Year
- MNY N/A
- CVKD 2023
- Fundamental
- Price
- MNY $1.68
- CVKD $10.54
- Analyst Decision
- MNY Strong Buy
- CVKD Strong Buy
- Analyst Count
- MNY 1
- CVKD 1
- Target Price
- MNY $4.00
- CVKD $32.00
- AVG Volume (30 Days)
- MNY 686.9K
- CVKD 27.7K
- Earning Date
- MNY 09-18-2025
- CVKD 08-11-2025
- Dividend Yield
- MNY N/A
- CVKD N/A
- EPS Growth
- MNY N/A
- CVKD N/A
- EPS
- MNY N/A
- CVKD N/A
- Revenue
- MNY $71,649,746.00
- CVKD N/A
- Revenue This Year
- MNY $16.97
- CVKD N/A
- Revenue Next Year
- MNY $19.35
- CVKD N/A
- P/E Ratio
- MNY N/A
- CVKD N/A
- Revenue Growth
- MNY N/A
- CVKD N/A
- 52 Week Low
- MNY $0.55
- CVKD $5.70
- 52 Week High
- MNY $2.15
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- MNY 60.41
- CVKD 37.37
- Support Level
- MNY $1.88
- CVKD $11.25
- Resistance Level
- MNY $2.13
- CVKD $11.88
- Average True Range (ATR)
- MNY 0.29
- CVKD 0.77
- MACD
- MNY 0.02
- CVKD -0.03
- Stochastic Oscillator
- MNY 58.77
- CVKD 2.95
About MNY MoneyHero Limited
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.